Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tucatinib + Trastuzumab in HER2-Altered Solid Tumors
NCT04579380Phase 2Active, not recruiting
- Sponsor
- Pfizer
- Start
- Jan 2021
- Primary completion
- Nov 2023
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 2, open-label, single-arm trial of tucatinib in solid tumor, sponsored by Pfizer. Primary endpoint: Confirmed Objective Response Rate up to 28.3 months. Started Jan 2021; status: active, not recruiting.
02
Drugs
tucatinib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04579380.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04579380.